The estimated Net Worth of Jonathan P Mow is at least $1.21 Million dollars as of 3 November 2021. Mr. Mow owns over 20,000 units of PhaseBio Pharmaceuticals stock worth over $11,696 and over the last 6 years he sold PHAS stock worth over $0. In addition, he makes $1,203,070 as Chief Executive Officer and Director at PhaseBio Pharmaceuticals.
Jonathan has made over 5 trades of the PhaseBio Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of PHAS stock worth $24,800 on 3 November 2021.
The largest trade he's ever made was exercising 39,044 units of PhaseBio Pharmaceuticals stock on 17 May 2019 worth over $69,108. On average, Jonathan trades about 9,004 units every 75 days since 2019. As of 3 November 2021 he still owns at least 166,850 units of PhaseBio Pharmaceuticals stock.
You can see the complete history of Mr. Mow stock trades at the bottom of the page.
Jonathan P. Mow serves as Chief Executive Officer, Director of the Company. Mr. Mow received a B.S. in mechanical engineering from the University of California, Berkeley and an M.B.A. from Carnegie Mellon University. Our Board of Directors believes that Mr. Mow is qualified to serve as a director based on his role as our Chief Executive Officer and his extensive management experience in the pharmaceutical industry.
As the Chief Executive Officer and Director of PhaseBio Pharmaceuticals, the total compensation of Jonathan Mow at PhaseBio Pharmaceuticals is $1,203,070. There are no executives at PhaseBio Pharmaceuticals getting paid more.
Jonathan Mow is 55, he's been the Chief Executive Officer and Director of PhaseBio Pharmaceuticals since 2014. There are 7 older and 9 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.
Jonathan's mailing address filed with the SEC is C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN, PA, 19355.
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp..., and Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include: